References of "Neven, P"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailThe 2006 Adjuvant Trastuzumab Convention in Belgium: 5 years later
VANDERHAEGEN, J; PARIDAENS, R; PICCART, M et al

Poster (2012, December)

Detailed reference viewed: 12 (1 ULg)
Full Text
Peer Reviewed
See detailTrastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authorities.
Van Vlaenderen, I.; Canon, J. L.; Cocquyt, V. et al

in Acta Clinica Belgica (2009), 64(2), 100-12

Trastuzumab (Herceptin, Roche) is a recombinant, humanized monoclonal antibody directed against the neu-HER2 protein, since May 2002 reimbursed in Belgium for the treatment of metastatic HER2+ breast ... [more ▼]

Trastuzumab (Herceptin, Roche) is a recombinant, humanized monoclonal antibody directed against the neu-HER2 protein, since May 2002 reimbursed in Belgium for the treatment of metastatic HER2+ breast cancer and since June 2007 also in adjuvant therapy of HER2+ early stage breast cancer. The purpose of this study was to estimate the cost-effectiveness from the Belgian health care payer perspective of reimbursing trastuzumab in the Latter indication. A Markov state transition model was designed to adequately capture the natural history and course of disease for early stage breast cancer patients, and to simulate cost and disease progression over a life time perspective. The model estimates differences in outcomes for patients treated with adjuvant trastuzumab during 1 year compared to current therapy, and captures cost consequences and health benefits of trastuzumab treatment. Health benefits were expressed in terms of quality-adjusted life years gained, and future benefits were discounted at 1.5%. Costs were calculated from the perspective of the Belgian authorities' health care budget, and future costs were discounted at 3%. Where relevant, the costs per Markov state were obtained from the IMS Hospital Disease database. Additionally, an expert opinion analysis on resource use during the follow-up of treated early breast cancer patients provided the cost estimates for states with minor or without hospital costs. The incremental cost-effectiveness ratio based on a life time simulation was estimated at Euro 10,315 per quality-adjusted life year gained. It can be concluded that trastuzumab treatment of HER2+ early stage breast cancer patients is cost-effective from the perspective of the Belgian health care authorities. [less ▲]

Detailed reference viewed: 32 (2 ULg)
Peer Reviewed
See detailConception et synthèse d’outils pharmacologiques originaux pour l’étude des récepteurs au thromboxane
Moray, A. L.; Dogne, J. M.; Neven, P. et al

Poster (2007, May)

Detailed reference viewed: 13 (1 ULg)
Peer Reviewed
See detailPharmacological evaluation of TP receptor antagonists by differential activity on alpha and beta isoforms
Hanson, Julien ULg; Dogne, J. M.; Ghiotto, J. et al

Poster (2006, November 18)

Detailed reference viewed: 1 (0 ULg)
Full Text
Peer Reviewed
See detailCharacterization of preferential activity on platelet thromboxane A2 receptors of BM-613, a new thromboxane A2 antagonist
Hanson, Julien ULg; Rolin, S.; De Leval, X. et al

in Fundamental & Clinical Pharmacology (2004)

Detailed reference viewed: 3 (1 ULg)
Full Text
Peer Reviewed
See detailSynthésis and pharmacological evaluation of original thromboxane A2 receptor antagonists derived from BM-573
Hanson, Julien ULg; Renard, Jean-François ULg; Neven, P. et al

in Fundamental & Clinical Pharmacology (2004)

Detailed reference viewed: 9 (2 ULg)
Peer Reviewed
See detailBM-613, a new thromboxane A2 antagonist, is characterized by a preferential activity on platelet thromboxane A2 receptors
Hanson, Julien ULg; Rolin, S.; De Leval, X. et al

Poster (2003, December)

Detailed reference viewed: 6 (0 ULg)
Peer Reviewed
See detailBM-613, a new thromboxane A2 antagonist, is characterized by a preferential activity on platelet thromboxane A2 receptors
Hanson, Julien ULg; Rolin, S.; De Leval, X. et al

Poster (2003, November 22)

Detailed reference viewed: 3 (1 ULg)
Peer Reviewed
See detailPharmacological evaluation of the thromboxane A2 receptor antagonist BM-613
Hanson, Julien ULg; Rolin, S.; De Leval, X. et al

Poster (2003, May)

Detailed reference viewed: 2 (0 ULg)
Peer Reviewed
See detailSynthesis and pharmacological evaluation of BM-613, an original thromboxane A2 antagonist
Hanson, Julien ULg; Rolin, S.; De Leval, X. et al

Poster (2003, May)

Detailed reference viewed: 2 (0 ULg)
Peer Reviewed
See detailEtude de la sélectivité tissulaire d’un nouvel antagoniste des récepteurs au thromboxane A2, le BM-613
Hanson, Julien ULg; Rolin, S.; De Leval, X. et al

Poster (2003, January 31)

Detailed reference viewed: 7 (0 ULg)
Full Text
Peer Reviewed
See detailEvaluation of classical NSAIDS on COX-1 and COX-2 purifies enzymes and prognosis of their effects on physiological responses.
De Leval, X.; Henrotin, Yves ULg; Masereel, B. et al

in Fundamental & Clinical Pharmacology (2003), 14

Detailed reference viewed: 1 (0 ULg)
Peer Reviewed
See detailEffects of thromboxane A2 receptor antagonists and thromboxane synthase inhibitors on osteogenic sarcoma cell induced platelet aggregation
De Leval, X.; Benoît, V.; Neven, P. et al

Poster (2002, October)

Detailed reference viewed: 6 (2 ULg)
Peer Reviewed
See detailEffects of thromboxane A2 receptor antagonists and thromboxane synthase inhibitors on osteogenic sarcoma cell induced platelet aggregation
De Leval, X.; Benoît, V.; Neven, P. et al

Poster (2002, May)

Detailed reference viewed: 6 (2 ULg)
Peer Reviewed
See detailEffects of thromboxane A2 receptor antagonists and thromboxane synthase inhibitors on osteogenic sarcoma cell-induced platelet aggregation
De Leval, X.; Benoit, V.; Neven, P. et al

Poster (2002, March 02)

Detailed reference viewed: 4 (1 ULg)
Peer Reviewed
See detailEvaluation of pyridinic sulfonamides related to nimesulide as COX-2 selective inhibitors
Julemont, F.; De Leval, X.; Neven, P. et al

Poster (2002, March 02)

Detailed reference viewed: 3 (0 ULg)